Mallinckrodt PLC appears to have found a path to eventually separate its branded portfolio from its specialty generics business as part of a proposed opioid settlement agreement that would result in the company’s generics subsidiaries filing for Chapter 11 bankruptcy, while the branded business would operate separately.
The proposed settlement, announced on 25 February, provides investors with some clarity on the path forward for Mallinckrodt, but there...








